Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) and Crescent Biopharma (NASDAQ:CBIO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.
Institutional & Insider Ownership
62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Mereo BioPharma Group and Crescent Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mereo BioPharma Group | N/A | -74.82% | -64.28% |
| Crescent Biopharma | N/A | -101.50% | -86.86% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mereo BioPharma Group | 2 | 3 | 3 | 0 | 2.12 |
| Crescent Biopharma | 1 | 1 | 2 | 2 | 2.83 |
Mereo BioPharma Group currently has a consensus target price of $1.67, suggesting a potential upside of 474.51%. Crescent Biopharma has a consensus target price of $29.60, suggesting a potential upside of 82.15%. Given Mereo BioPharma Group’s higher probable upside, equities research analysts plainly believe Mereo BioPharma Group is more favorable than Crescent Biopharma.
Risk and Volatility
Mereo BioPharma Group has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Earnings and Valuation
This table compares Mereo BioPharma Group and Crescent Biopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mereo BioPharma Group | $500,000.00 | 92.65 | -$41.88 million | ($0.04) | -7.25 |
| Crescent Biopharma | $10.84 million | 55.68 | -$153.94 million | ($6.72) | -2.42 |
Mereo BioPharma Group has higher earnings, but lower revenue than Crescent Biopharma. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.
About Mereo BioPharma Group
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
About Crescent Biopharma
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.
